Model N

Model N competes with in-house spreadsheets and legacy ERP modules, as well as specialized vendors like Vista Equity-backed Blue Sun (formerly Opus) and smaller niche providers in pharma pricing. In high tech, competitors include SAP's channel management tools and specialty distributors. No single competitor dominates the fragmented revenue management software market.

No, Model N has been publicly traded since its IPO in 2013 (NYSE: MODN). In 2021, activist investor Sachem Head Capital took a stake and pushed for operational changes, but the company remains independent. There are no disclosed plans for a take-private transaction.

Model N focuses on three verticals: pharmaceutical and biotech companies (for gross-to-net pricing, government pricing, and rebate management), medical device manufacturers (for tendering and channel rebates), and high-tech electronics companies (for global price management and channel incentive tracking). Semiconductor clients formed a significant portion of the high-tech segment as of 2023 earnings calls.

No, Model N is a pure software and services company. It maintains cash reserves and marketable securities on its balance sheet but does not operate as an investment vehicle. There is no family office, asset management wing, or investment arm.

Model N offers managed services where its staff directly execute government price reporting and audit preparation on behalf of clients. This includes filing state price transparency reports, calculating Medicaid rebates, and preparing for federal audits. The service model transfers liability for timely and accurate filings to Model N under contractual terms.